Apollo in talks for $20bn takeover of J&J orthopaedics unit DePuy Synthes

M&A · Partnership Impact 4
โดย Medical Device Network·US·Read original
Summary · why it matters

Apollo Global Management is reportedly in non-binding talks to acquire Johnson & Johnson's orthopaedics business, DePuy Synthes, for nearly $20bn, according to Bloomberg, which first reported the development. Anonymous sources said an agreement could be reached within several weeks, though the talks could also end without a deal or attract another bidder, and DePuy Synthes has drawn interest from several private equity companies. If signed, it would be Apollo's largest healthcare deal to date. The talks come as J&J works to separate itself from DePuy Synthes following its 2025 spinout announcement; the unit posted $9.3bn in sales last year and was created through J&J's $21bn takeover of Swiss company Synthes in 2012, which was combined with its own DePuy business. GlobalData medical devices research director Andrew Thompson called a $20bn deal a low end value, noting J&J bought Synthes in 2011 for $19.7bn and DePuy was a $3.5bn acquisition from Roche in 1998, and said a rival bid would likely come from another private equity group or consortium rather than Stryker or Zimmer due to regulatory hurdles. Neither J&J nor Apollo immediately responded to a request for comment.

Impact on stocks 5

Aging Population▲ · 2 stocks
Biotech & Genomic Medicine▲ · 1 stocks
Johnson & Johnson
JNJ
▲ PositiveCapitalrelevance

J&J is in talks to sell its DePuy Synthes orthopaedics unit for nearly $20bn as it works to separate from the business after its 2025 spinout announcement.

Cloud & Digital Infrastructure▲ · 1 stocks
Health Care▲ · 1 stocks

Theme Impact 1

Related news

IR-MED and Dice Technologies Sign LOI to Bring PressureSafe to Japan

IR-MED Ltd. and Dice Technologies Co., Ltd. announced the signing of a letter of intent to cooperate on the evaluation, research support, localization, commercialization preparation and regulatory preparation of IR-MED's PressureSafe medical device in Japan. The LOI is not intended to create legally binding obligations between the parties, except for provisions relating to confidentiality and data protection, intellectual property rights, and device management, return and disposal. The collaboration targets a Japanese market that includes more than 36 million people aged 65 and older, approximately 8,000 hospitals, 13,600 long-term care facilities, and 16,000 or more home-visit nursing stations. Dice Technologies, based in Osaka, will lead and coordinate the evaluation program in Japan, leveraging a nationwide footprint serving over 1,000 clinics, and will support Pharmaceuticals and Medical Devices Agency consultation preparation while integrating PressureSafe data into its CareNest platform and domestic Electronic Health Records. Clinical research and evidence-generation activities are expected to include cooperation with the Department of Plastic Surgery at Kobe University, subject to required ethics review, institutional approvals and separate written arrangements. IR-MED's PressureSafe combines infrared spectroscopy with a proprietary algorithm to support assessment of early signs of pressure injuries, and the partners intend to evaluate it in hospitals, long-term care facilities and home healthcare settings.
2696.HK
Aging Population
GlobeNewswire·2dRead more →
▲2

Edwards Lifesciences Praises Updated CMS Coverage Decision for TAVR

Edwards Lifesciences said an updated CMS national coverage determination will ease patient access to transcatheter aortic valve replacement. Under the new NCD, CMS will cover TAVR for symptomatic severe aortic valve stenosis without the coverage with evidence development requirement, while expanding coverage to asymptomatic severe aortic stenosis with coverage with evidence development. The policy also revises coverage criteria for pre-procedural patient assessment, intraoperative requirements, and operator and hospital procedural volume requirements. Edwards said it is pleased the updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team, and that the modernized policy supports a more streamlined patient care journey and gives Heart Teams greater flexibility in patient evaluation and treatment. The company added that it has confidence in its 2026 guidance, with 2027 guidance to come in December at its investor conference.
EW ▲
Aging Population ▲
Seeking Alpha·8dRead more →
3

Apple unveils Apple Watch Series 12 and Ultra 4 with new health features

Apple has announced its most advanced health and fitness experience yet, introducing the Apple Watch Series 12 and Apple Watch Ultra 4 with a new Health Sensing System that delivers the most accurate heart rate sensing in a wearable, along with a redesigned Health app powered by Apple Intelligence. The new watches measure heart rate every five seconds and HRV as often as every five minutes, 24 times more frequently, and introduce a readiness score from 0 to 10 with recommendations like Recover or Go For It. The redesigned Health app, coming later this year with iOS 27, adds an Insights tab and a Longevity tab featuring Health Age, which compares users' metrics to their chronological age. Users can also schedule and purchase lab tests covering over 50 biomarkers for $119 at approximately 2,000 Quest Diagnostics locations in the U.S., and new movement assessments use the iPhone camera and Apple Watch for at-home evaluations. The watches also support perimenopause and menopause tracking, and watchOS 27 will be available starting September 14 for Apple Watch Series 9 or later, Apple Watch SE 3, and Apple Watch Ultra 2 or later.
AAPL ▲
Longevity & Life Extension ▲Aging Population
Business Wire·9dRead more →
© 2026 MarketDXNews